Wir sind mit live! Mehr erfahren

Integra LifeSciences

IART

Börsenwert 1,03 Mrd. $

13,21 USD

-0,32

2,37 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

13,21

0,00

0 %

1 Tag

-2,37 %

5 Tage

-1,64 %

1 Monat

-17,75 %

3 Monate

-33,45 %

6 Monate

21,86 %

Seit Jahresbeginn

9,99 %

1 Jahr

-9,58 %

5 Jahre

-80,48 %

10 Jahre

-67,29 %

Profil: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

Mitarbeiter: 4.427

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 38,2 %

Neutral 55,9 %

Negativ 5,9 %

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California.

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop

NEW YORK--(BUSINESS WIRE)---- $IART #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On October 2, 2026, Integra released its third quarter 2026 financial results,.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 21.2% Share Drop

INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Integra (IART) To Contact Him Directly To Discuss Their Options

INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Integra securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation. There is no cost or obligation.

Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline

Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline

San Diego, California--(Newsfile Corp. - October 4, 2026) - Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation.

Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline

Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)

A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.

Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)

Proactive Investors

Integra LifeSciences lowers revenue and earnings outlook for 2026

Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.

Integra LifeSciences lowers revenue and earnings outlook for 2026

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt